Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day

Zoetis faces ongoing headwinds but is now considered a cautious 'Buy' as valuation reflects low-to-m

Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance des

Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my

Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Corient Private Wealth LP lowered its stake in Zoetis Inc. (NYSE: ZTS) by 8.9% in the second quarter

Zoetis (NYSE: ZTS - Get Free Report) and Urogen Pharma (NASDAQ: URGN - Get Free Report) are both hea

Michael Burry, a hedge fund manager and investor known for predicting the 2008 financial crash, has

HB Wealth Management LLC increased its stake in shares of Zoetis Inc. (NYSE: ZTS) by 190.0% during t

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced tha

Phibro Animal Health's Zoetis MFA acquisition has created a larger animal health platform with stron

Blackhill Capital Inc. cut its stake in shares of Zoetis Inc. (NYSE: ZTS) by 28.8% in the undefined

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target

These stocks have been generous with their dividend increases, and more may be on the way.

Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic tr

Zoetis' Q2 earnings results were mixed, and the company cut its forward guidance. This has reduced t

Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross marg

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Simparica

The U.S. Food and Drug Administration on Thursday issued an emergency use authorization for Zoetis'

https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-trea

BNP Paribas analyst Navann Ty maintains Zoetis (NYSE:ZTS) with a Outperform and lowers the price

Zoetis (NYSE: ZTS) reported second-quarter revenue of $2.5 billion, flat on a reported basis and dow

Zoetis Inc. (NYSE: ZTS - Get Free Report)'s stock price hit a new 52-week low during mid-day trading

Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the

U.S. stocks close higher on Friday, with Nasdaq up 300 points and S&P 500 at record high. Benzin

UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target

JP Morgan analyst Chris Schott maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price

Zoetis beat second-quarter earnings estimates but missed on revenue, cut 2026 guidance and cited wea

Zoetis (NYSE:ZTS) lowers FY2026 Adj EPS guidance from $6.85-$7.00 to $6.15-$6.25 vs $6.88 analyst es

Zoetis (NYSE:ZTS) reported quarterly earnings of $1.87 per share which beat the analyst consensus es

Michael Burry expands short positions against Nvidia and AI, while piling into de-risked value stock

UBS analyst Andrea Alfonso maintains Zoetis (NYSE:ZTS) with a Neutral and lowers the price target

Morgan Stanley analyst Erin Wright maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the p

Zoetis Inc. (NYSE:ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and

The Australian agency is conducting a Phase 2 assessment of Zoetis' $160 million acquisition of

July 15, 2026 records indicate that Representative Byron Donalds filed a sale of Cadence Design Syst

Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services

Recombinant vector vaccine protects chickens against Newcastle disease and Marek's disease in a

Barclays analyst Glen Santangelo maintains Zoetis (NYSE:ZTS) with a Equal-Weight and lowers the p

TD Cowen analyst Steve Scala maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price target f

Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target

Cramer says Zoetis has issues. Prefers this stock in animal health industry. Energy Transfer is in a

The health care sector's most oversold stocks are a buying opportunity due to undervalued compan

Get the latest analyst rating changes for top companies on Wall Street, including upgrades and downg

Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target

https://www.fda.gov/animal-veterinary/cvm-updates/fda-issues-emergency-use-authorization-over-counte

Citigroup analyst Daniel Grosslight maintains Zoetis (NYSE:ZTS) with a Buy and lowers the price t